Pharmaceutical Executive January 14, 2026
Mike Hollan

Key Takeaways

  • Eli Lilly is leveraging its GLP-1 success and direct-to-consumer strategies to strengthen its market position amid patent challenges.
  • The company is diversifying its portfolio with drugs targeting obesity, diabetes, and other conditions, aiming to impact 1 billion people.
  • A partnership with NVIDIA aims to transform drug discovery using AI, combining Lilly’s data with NVIDIA’s computational expertise.
  • Lilly Direct has become a significant platform for direct patient engagement, with substantial consumer adoption of GLP-1 medications.

David Ricks detailed how the company plans to build on the success of Zepbound and Lilly Direct.

Eli Lilly came to the 44th annual JP Morgan Healthcare Conference bolstered by a strong year.1 While the looming patent cliff still impacts that company’s...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Related Articles:
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety
Introducing the Sunday Times Tech 100: Life sciences part 1
China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says

Share Article